Navigation Links
GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas

LAS VEGAS, July 23, 2014 /PRNewswire/ -- GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and development company, announced today that it is filing for two medical marijuana dispensary locations in Las Vegas, Nevada. These locations are in addition to the Clark County, Nevada dispensary for which the company has received a special use permit, as previously announced. 

GrowBLOX Sciences' CEO Craig Ellins stated, "We are pleased to be submitting two new applications for dispensaries in the City of Las Vegas. We believe that working with our local partners has produced strong applications and we love our chosen locations."  GrowBLOX strategically chose the two locations in its latest application to capitalize on future heavy Las Vegas medical tourism.

If approved, the Rainbow-Vista dispensary will be located at 1040 South Rainbow Boulevard, Las Vegas and the Vegas-Charleston dispensary at 905 South Las Vegas Boulevard, Las Vegas. Both locations are in the heart of the city and well-suited for servicing the medical marijuana patients who are among the 40 million tourists visiting the city each year.

Craig Ellins added, "The City of Las Vegas and the State of Nevada have created very rigorous application processes, which we appreciate because it brings the standard of operations up to a high level for our industry.  We want to make Nevada our flagship market."

GrowBLOX has already received both a special use permit for a medical marijuana dispensary in Fort Apache, Nevada (Clark County) as well as a special use permit for a cannabis cultivation and conversion facility; also in Clark County, NV.  The Company is awaiting final State approval, expected later this year, for both the dispensary and the cultivation facility.  If both licenses are granted, and allowing some time for construction, GrowBLOX expects to be generating revenues from the cultivation and sale of legal medical cannabis in the second half of 2015.

Mr. Ellins commented, "We anticipate getting a response on our application for two additional dispensaries in the first quarter of 2015, although the timing of a response is outside of our control.  We are very excited about the prospect of adding to our Nevada presence.  This is part of our strategy of securing the rights to dispensaries and grow-sites nationwide. As we've previously announced, we have similar expansion efforts in Florida, Illinois, New York and elsewhere.  We look forward to updating our shareholders as we continue to execute on our business plan." 

About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation.  The GrowBLOXTM chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product.  The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions.

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are inherently unreliable and actual results may differ materially.  Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Jonathan Barkman
Riverview Capital Enterprises

SOURCE GrowBLOX Sciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
2. VG Life Sciences, Inc. Update on Phase I Cancer Study
3. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
4. Pressure BioSciences, Inc. to Discuss Third Quarter 2013 Financial Results and Provide a Business Update
5. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
6. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
7. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
8. MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the American Society of Dermatologic Surgery Annual Meeting
9. VG Life Sciences, Inc. Closes on $2,235,000 from Private Fund
10. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
11. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... and NEW YORK , November 24, ... investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will work ... immuno-oncology and other areas of unmet medical need. The collaboration ... LSP 5, the latest LSP fund. This is the first ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... ... 23, 2015 , ... Shimadzu Corporation announces that it has ... Chromatography system. The award from R&D magazine recognizes Shimadzu’s Nexera UC system as ... the analytical and testing category. R&D Magazine chose the Nexera UC system because ...
(Date:11/23/2015)... England and PISCATAWAY, New ... Cambridge Crystallographic Data Centre (CCDC) ... the Cambridge Structural Database (CSD) and the CSD-System, ... for researchers worldwide: CSD-Discovery to support the discovery ... crystalline materials, and CSD-Enterprise, the complete set of ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):